French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Karine Danno
- Phone Number: +33 (04) 72 66 93 33
- Email: descar-t@lysarc.org
Study Locations
-
-
-
Amiens, France
- Recruiting
- CHU d'Amiens - Hôpital Sud
-
Contact:
- Magalie JORIS, MD
- Phone Number: +33 (0)3 22 45 60 00
- Email: joris.magalie@chu-amiens.fr
-
Angers, France
- Recruiting
- CHU Angers
-
Contact:
- Aline TANGUY-SCHMIDT, MD
- Email: alschmidt@chu-angers.fr
-
Besançon, France
- Recruiting
- CHRU Besançon - Hôpital Minjoz
-
Contact:
- Adrien CHAUCHET, MD
-
Brest, France
- Recruiting
- CHU de Brest - Hôpital du Morvan
-
Contact:
- Adrian TEMPESCUL, MD
- Email: adrian.tempescul@chu-brest.fr
-
Caen, France
- Recruiting
- Institut d'Hématologie de Basse Normandie
-
Contact:
- Ghandi DAMAJ, Pr
- Email: damaj-gl@chu-caen.fr
-
Clermont-Ferrand, France
- Recruiting
- CHU d'Estaing
-
Contact:
- Jacques-Olivier BAY, Pr
- Phone Number: +33 (0)4 73 75 00 65
- Email: jobay@chu-clermontferrand.fr
-
Créteil, France
- Recruiting
- APHP - Hopital Henri Mondor
-
Contact:
- Fabien LE BRAS, MD
- Phone Number: +33 (0)1 49 83 65 05
- Email: fabien.le-bras@aphp.fr
-
Dijon, France
- Recruiting
- CHU de Dijon
-
Contact:
- Olivier CASASNOVAS, MD
- Phone Number: +33 (0)3 80 29 50 41
- Email: olivier.casasnovas@chu-dijon.fr
-
La Tronche, France
- Recruiting
- CHU de GRENOBLE
-
Contact:
- Sylvain CARRAS, MD
- Phone Number: +33 (0)4 76 76 57 55
- Email: scarras@chu-grenoble.fr
-
Lille, France
- Recruiting
- CHRU de Lille - Hôpital Claude Hurriez
-
Contact:
- Ibrahim YAKOUB-AGHA, Pr
- Phone Number: +33 (0)3 20 44 42 84
- Email: ibrahim.yakoubagha@chru-lille.fr
-
Limoges, France
- Recruiting
- Hopital Dupuytren
-
Contact:
- Julie ABRAHAM, MD
- Phone Number: +33 (0)5 55 05 66 51
- Email: julie.abraham@chu-limoges.fr
-
Lyon, France
- Recruiting
- Centre Léon Bérard
-
Lyon, France
- Recruiting
- Institut d'Hématologie et d'Oncologie Pédiatrique (IHOP)
-
Contact:
- Yves BERTRAND, Pr
- Email: yves.bertrand@ihope.fr
-
Marseille, France
- Recruiting
- Hôpital de la Timone
-
Contact:
- Arthur STERIN, MD
- Email: arthur.sterin@aph-m.fr
-
Marseille, France
- Recruiting
- Institut Paoli Calmette
-
Contact:
- Aude Collignon, MD
-
Montpellier, France
- Recruiting
- CHU de Montpellier
-
Contact:
- Guillaume CARTRON, Pr
- Phone Number: +33(0)4 67 33 67 33
- Email: guillaume.cartron@orange.fr
-
Nantes, France
- Recruiting
- CHU de Nantes - Hôtel Dieu
-
Contact:
- Thomas GASTINNE, MD
- Phone Number: +33 (0)2 40 08 33 02
- Email: thomas.gastinne@chu-nantes.fr
-
Nice, France
- Recruiting
- Chu De Nice
-
Contact:
- Michaël LOSCHI, MD
- Phone Number: +33 (0)4 92 03 90 25
- Email: loschi.m@chu-nice.fr
-
Paris, France
- Recruiting
- APHP - Hôpital Cochin
-
Contact:
- Jérémie ZERBIT, Dr
- Email: jeremie.zerbit@aphp.fr
-
Paris, France
- Recruiting
- APHP - Hôpital Saint Antoine
-
Contact:
- Mohamad MOHTY, Pr
- Phone Number: +33 (0)1 49 28 26 20
- Email: mohamad.mohty@inserm.fr
-
Paris, France
- Recruiting
- APHP - Hôpital Necker
-
Contact:
- Olivier HERMINE, Pr
- Phone Number: +33 (0)1 44 49 51 98
- Email: olivier.hermine@aphp.fr
-
Paris, France
- Recruiting
- APHP - Hopital Saint Louis
-
Contact:
- Catherine THIEBLEMONT, Pr
- Phone Number: +33 (0) 1 42 49 98 37
- Email: catherine.thieblemont@aphp.fr
-
Paris, France
- Recruiting
- APHP - Hôpital La Pitié Salpêtrière
-
Contact:
- Sylvain CHOQUET, MD
- Phone Number: +33 (0)1 42 16 28 26
- Email: sylvain.choquet@aphp.fr
-
Paris, France
- Recruiting
- APHP - Hôpital Universitaire Robert Debré
-
Contact:
- André BARUCHEL, Pr
- Phone Number: +33 (0)1 40 03 53 88
- Email: andre.baruchel@aphp.fr
-
Pessac, France
- Recruiting
- Centre Francois Magendie
-
Contact:
- Kamal BOUABDALLAH, MD
- Phone Number: +33 (0)5 57 65 65 11
- Email: kamal.bouabdallah@chu-bordeaux.fr
-
Pierre-Bénite, France
- Recruiting
- Centre Hospitalier LYON SUD
-
Contact:
- Emmanuel BACHY, Pr
- Phone Number: +33 (0)4 78 86 43 01
- Email: emmanuel.bachy@chu-lyon.fr
-
Poitiers, France
- Recruiting
- Hôpital de la Milétrie - CHU de Poitiers
-
Contact:
- Xavier LELEU, Pr
- Phone Number: +33 (0)5 49 44 46 89
- Email: xavier.leleu@chu-poitiers.fr
-
Rennes, France
- Recruiting
- CHU De Rennes - Hôpital Pontchaillou
-
Contact:
- Thierry LAMY-DE-LA-CHAPELLE, Pr
- Phone Number: +33 (0)2 99 28 42 91
- Email: thierry.lamy.de.la.chapelle@chu-rennes.fr
-
Rouen, France
- Recruiting
- Centre Henri Becquerel
-
Contact:
- Fabrice JARDIN, Pr
- Phone Number: +33 (0)2 32 08 24 65
- Email: fabrice.jardin@chb.unicancer.fr
-
Rouen, France
- Recruiting
- CHU de Rouen Normandie
-
Contact:
- Nimrod BUCHBINDER, MD
- Email: Nimrod.Buchbinder@chu-rouen.fr
-
Saint-Priest-en-Jarez, France
- Recruiting
- Institut de Cancérologie Hématologie Universitaire de Saint Etienne
-
Contact:
- Ludovic FOUILLET, MD
- Email: ludovic.fouillet@icloire.fr
-
Strasbourg, France
- Recruiting
- ICANS (Institut de Cancérologie Strasbourg Europe)
-
Contact:
- Blandine GUFFROY, MD
- Email: b.guffroy@icans.eu
-
Toulouse, France
- Recruiting
- Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)
-
Contact:
- Pierre BORIES, MD
- Phone Number: +33 (0)5 31 15 65 14
- Email: bories.pierre@iuct-oncopole.fr
-
Tours, France
- Recruiting
- CHU Bretonneau
-
Contact:
- Emmanuel GYAN, MD
- Phone Number: +33 (0)2 47 47 37 12
- Email: e.gyan@chu-tours.fr
-
Vandœuvre-lès-Nancy, France
- Recruiting
- CHU Brabois
-
Contact:
- Marie-Thérèse RUBIO, Pr
- Phone Number: +33 (0)3 83 15 32 82
- Email: m.rubio@chru-nancy.fr
-
Principal Investigator:
- Marie-Thérèse RUBIO, Pr
-
Principal Investigator:
- Cécile POCHON, MD
-
Villejuif, France
- Recruiting
- Gustave Roussy Cancer Campus
-
Contact:
- Cristina CASTILLA LLORENTE, MD
- Phone Number: +33 (0)1 42 11 42 39
- Email: cristina.castilla-llorente@gustaveroussy.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Retrospective inclusion :
- Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center
- If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive
Prospective inclusion :
- Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center.
- Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019
- Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019
- If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive.
Exclusion Criteria Patient not registered with the social security in France
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
overall survival from eligibility
Time Frame: 15 years
|
15 years
|
|
Overall survival from administration
Time Frame: 15 years
|
15 years
|
|
complete response rate
Time Frame: 15 years
|
15 years
|
|
Progression free survival
Time Frame: 15 years
|
15 years
|
|
Duration of response
Time Frame: 15 years
|
15 years
|
|
Delays between patient eligibility and CAR-T treatment
Time Frame: 15 years
|
15 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Steven LE GOUILL, Pr, Institut Curie
- Principal Investigator: Roch HOUOT, Pr, CHU Pontchaillou
Publications and helpful links
General Publications
- Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22.
- Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, Malard F, Petillon MO, Manier S, Yakoub-Agha I, Caillot D, Lafon I, Leleu X, Moya N, Royer B, Schiano De Colella JM, Brisou G, Touzeau C, Perrot A, Bories P, Vincent L, Guedon H, Decaux O, Ferment B, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Avet-Loiseau H, Moreau P, Arnulf B. Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. Blood Adv. 2026 Feb 24;10(4):1324-1333. doi: 10.1182/bloodadvances.2025017597.
- Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, Malard F, Petillon MO, Manier S, Yakoub-Agha I, Caillot D, Lafon I, Leleu X, Moya N, Royer B, Schiano De Colella JM, Brisou G, Touzeau C, Perrot A, Bories P, Vincent L, Guedon H, Decaux O, Ferment B, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Avet-Loiseau H, Moreau P, Arnulf B. Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. Blood Adv. 2026 Feb 24;10(4):1324-1333. doi: 10.1182/bloodadvances.2025017597.
- Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, Brisou G, Gros FX, le Bras F, Bories P, Choquet S, Rubio MT, Iacoboni G, O'Reilly M, Casasnovas RO, Bay JO, Mohty M, Joris M, Abraham J, Castilla Llorente C, Loschi M, Carras S, Chauchet A, La Rochelle LD, Hermine O, Guidez S, Cony-Makhoul P, Fogarty P, Le Gouill S, Morschhauser F, Gastinne T, Cartron G, Subklewe M, Locke FL, Sanderson R, Barba P, Houot R, Bachy E. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol. 2024 Aug 6;17(1):61. doi: 10.1186/s13045-024-01579-w.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- DESCAR-T
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.